Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Bob Carpenter
AddedMar 31, 2024
UpdatedMay 31, 2026
Bob Carpenter

Bob Carpenter

Founder, Boston Medical Investors

Crunchbase

Bob Carpenter's Career

Boston Medical Investors
Boston Medical Investors

Brookline, MA, US

Founder
Immuneering
Immuneering

Cambridge, MA, US

Board Member· Board
Aquinnah Pharmaceuticals
Aquinnah Pharmaceuticals

Cambridge, MA, US

Board Member· Board
SynapDx
SynapDx

Lexington, MA, US

Board Member· Board
Hydra Biosciences
Hydra Biosciences

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Bob Carpenter's Career

Boston Medical Investors
Boston Medical Investors
Investment FirmInvestment Firm51994Brookline, MA, US
Founder
Immuneering
Immuneering
Public$87.2M792008Cambridge, MA, US
Board Member· Board

Leadership at Immuneering

Diana HausmanDiana HausmanBoard Member
Laurie KeatingLaurie KeatingBoard Member
Ben ZeskindBen ZeskindBoard Member

Similar to Immuneering

INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
ImmunityBioImmunityBioSan Diego, CA, USCancer Treatment, Immunotherapyest. 2014ImmunityBioSan Diego, CA, US · est. 2014

ImmunityBio: A biotech firm innovating cell and immunotherapy products to enhance natural immunity against diseases.

Public · $1.1B587
ImmunoGenesisImmunoGenesisHouston, TX, USCancer Therapiesest. 2019ImmunoGenesisHouston, TX, US · est. 2019

ImmunoGenesis: Developing science-based therapies to combat immune-resistant tumors.

Public · $28M38
ImmunomeImmunomeExton, PA, USCancer Therapiesest. 2008ImmunomeExton, PA, US · est. 2008

Immunome, a Philadelphia-based biotech company, develops innovative cancer immunotherapies.

Public · $218.9M48
Aquinnah Pharmaceuticals
Aquinnah Pharmaceuticals
Pre-Seed$19.8M302014Cambridge, MA, US
Board Member· Board

Leadership at Aquinnah Pharmaceuticals

Glenn LarsenGlenn LarsenFounder
Duane BurnettDuane BurnettBoard Member
Dr Glenn R Larsen PhDDr Glenn R Larsen PhDBoard Member

Similar to Aquinnah Pharmaceuticals

Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262
Aquavit PharmaceuticalsAquavit PharmaceuticalsNew York City, NY, USMedical Devices, Pharmaceuticalsest. 2010Aquavit PharmaceuticalsNew York City, NY, US · est. 2010

Aquavit Pharmaceuticals: Innovating personalized medicine and modern healthcare solutions.

Public · $330k15
AdrxAdrxThousand Oaks, CA, USDrug Discoveryest. 2013AdrxThousand Oaks, CA, US · est. 2013

ADRx, Inc.: A California-based biopharmaceutical firm innovating novel drugs for amyloid diseases.

Series A · $24.3M9
Woolsey PharmaceuticalsWoolsey PharmaceuticalsNew York City, NY, USPharmaceuticalsest. 2019Woolsey PharmaceuticalsNew York City, NY, US · est. 2019

Woolsey Pharmaceuticals: Innovating treatments for challenging diseases, accelerating global health solutions.

Series B · $28.3M9
SynapDx
SynapDx
Series B$32.4M112010Lexington, MA, US
Board Member· Board

Leadership at SynapDx

Hemant TanejaHemant TanejaBoard Member
Stanley LapidusStanley LapidusBoard Member
Kevin HrusovskyKevin HrusovskyBoard Member
Tom Mac MahonTom Mac MahonBoard Member
Hydra Biosciences
Hydra Biosciences
Acquired$94.9M02001Cambridge, MA, US
Board Member· Board

Leadership at Hydra Biosciences

Vincent MilesVincent MilesBoard Member
Jean GeorgeJean GeorgeBoard Member
Dean LiDean LiFounder
Russell HerndonRussell HerndonBoard Member
Samuel WuSamuel WuBoard Member
Steve HallSteve HallBoard Member

Bob Carpenter's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Bob Carpenter

Michael MoeMichael MoeBoard Member · TAL Education GroupRonald GoldRonald GoldBoard Member · NJ BioLouis V GerstnerLouis V GerstnerBoard Member · Memorial Sloan Kettering Cancer CenterMatthew ChervenakMatthew ChervenakCo-Founder · Sunwater CapitalMatt ElsonMatt ElsonFounder · Benchmark Cloud AccountingRick GibsonRick GibsonCEO · CopperKey